Description:Acrizanib, identified by its CAS number 1229453-99-9, is a small molecule that belongs to the class of compounds known as kinase inhibitors. It is primarily investigated for its potential therapeutic applications in oncology, particularly in the treatment of various cancers by targeting specific signaling pathways involved in tumor growth and proliferation. Acrizanib exhibits a unique mechanism of action by inhibiting certain kinases, which play a crucial role in cell signaling and regulation. The compound is characterized by its ability to selectively bind to its target enzymes, thereby disrupting their activity and leading to reduced tumor cell viability. In terms of physical properties, Acrizanib is typically described as a solid at room temperature, with specific solubility characteristics that may vary based on the solvent used. Its pharmacokinetic profile, including absorption, distribution, metabolism, and excretion, is an important area of study to determine its efficacy and safety in clinical settings. Ongoing research continues to explore its full potential and optimize its use in cancer therapy.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
